Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $280.78 billion. The enterprise value is $321.62 billion.
| Market Cap | 280.78B |
| Enterprise Value | 321.62B |
Important Dates
The next estimated earnings date is Thursday, July 16, 2026, before market open.
| Earnings Date | Jul 16, 2026 |
| Ex-Dividend Date | Mar 11, 2026 |
Share Statistics
Novartis AG has 1.91 billion shares outstanding. The number of shares has decreased by -3.80% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.91B |
| Shares Change (YoY) | -3.80% |
| Shares Change (QoQ) | -0.67% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 39.23% |
| Float | 1.74B |
Valuation Ratios
The trailing PE ratio is 20.75 and the forward PE ratio is 16.66.
| PE Ratio | 20.75 |
| Forward PE | 16.66 |
| PS Ratio | 4.96 |
| Forward PS | n/a |
| PB Ratio | 7.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.01 |
| P/OCF Ratio | 14.64 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.03, with an EV/FCF ratio of 18.34.
| EV / Earnings | 23.76 |
| EV / Sales | 5.68 |
| EV / EBITDA | 14.03 |
| EV / EBIT | 17.46 |
| EV / FCF | 18.34 |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 1.21.
| Current Ratio | 0.85 |
| Quick Ratio | 0.53 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | 2.03 |
| Debt / FCF | 2.68 |
| Interest Coverage | 15.14 |
Financial Efficiency
Return on equity (ROE) is 34.93% and return on invested capital (ROIC) is 21.10%.
| Return on Equity (ROE) | 34.93% |
| Return on Assets (ROA) | 10.54% |
| Return on Invested Capital (ROIC) | 21.10% |
| Return on Capital Employed (ROCE) | 21.14% |
| Weighted Average Cost of Capital (WACC) | 6.26% |
| Revenue Per Employee | $751,697 |
| Profits Per Employee | $179,813 |
| Employee Count | 75,267 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, Novartis AG has paid $2.27 billion in taxes.
| Income Tax | 2.27B |
| Effective Tax Rate | 14.38% |
Stock Price Statistics
The stock price has increased by +29.64% in the last 52 weeks. The beta is 0.49, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +29.64% |
| 50-Day Moving Average | 149.18 |
| 200-Day Moving Average | 141.77 |
| Relative Strength Index (RSI) | 57.90 |
| Average Volume (20 Days) | 1,630,047 |
Short Selling Information
The latest short interest is 4.54 million, so 0.24% of the outstanding shares have been sold short.
| Short Interest | 4.54M |
| Short Previous Month | 4.49M |
| Short % of Shares Out | 0.24% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.55 |
Income Statement
In the last 12 months, Novartis AG had revenue of $56.58 billion and earned $13.53 billion in profits. Earnings per share was $6.98.
| Revenue | 56.58B |
| Gross Profit | 42.75B |
| Operating Income | 18.42B |
| Pretax Income | 15.78B |
| Net Income | 13.53B |
| EBITDA | 22.92B |
| EBIT | 18.42B |
| Earnings Per Share (EPS) | $6.98 |
Balance Sheet
The company has $6.89 billion in cash and $47.00 billion in debt, with a net cash position of -$40.11 billion or -$21.02 per share.
| Cash & Cash Equivalents | 6.89B |
| Total Debt | 47.00B |
| Net Cash | -40.11B |
| Net Cash Per Share | -$21.02 |
| Equity (Book Value) | 38.93B |
| Book Value Per Share | 20.18 |
| Working Capital | -4.77B |
Cash Flow
In the last 12 months, operating cash flow was $19.18 billion and capital expenditures -$1.64 billion, giving a free cash flow of $17.54 billion.
| Operating Cash Flow | 19.18B |
| Capital Expenditures | -1.64B |
| Depreciation & Amortization | 4.50B |
| Net Borrowing | 14.53B |
| Free Cash Flow | 17.54B |
| FCF Per Share | $9.19 |
Margins
Gross margin is 75.55%, with operating and profit margins of 32.56% and 23.92%.
| Gross Margin | 75.55% |
| Operating Margin | 32.56% |
| Pretax Margin | 27.90% |
| Profit Margin | 23.92% |
| EBITDA Margin | 40.51% |
| EBIT Margin | 32.56% |
| FCF Margin | 30.99% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.01%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 2.01% |
| Dividend Growth (YoY) | 18.68% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 44.14% |
| Buyback Yield | 3.80% |
| Shareholder Yield | 5.81% |
| Earnings Yield | 4.82% |
| FCF Yield | 6.25% |
Analyst Forecast
The average price target for Novartis AG is $153.87, which is 0.52% higher than the current price. The consensus rating is "Hold".
| Price Target | $153.87 |
| Price Target Difference | 0.52% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 4.35% |
| EPS Growth Forecast (3Y) | 6.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novartis AG has an Altman Z-Score of 3.27 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.27 |
| Piotroski F-Score | 5 |